SKU: B079-10MG  / 
    CAS Number: 1985606-14-1

    Baloxavir Marboxil


    Baloxavir Marboxil is a synthetic antiviral compound. It has activity against viruses causing influenza A and influenza B. It originated by Shionogi (Japan).

    It is a small molecule inhibitor of cap-dependent endonuclease found in of influenza A and B viruses. It is a pro-drug that is converted via hydrolysis to its active form, Baloxavir Acid.

    Baloxavir Marboxil is soluble in DMSO.

    Mechanism of Action Baloxavir Marboxil has a unique mechanism of action as a cap-dependent endonuclease inhibitor. It inhibits the process called cap snatching, which is a mechanism used by viruses to hijack the host’s mRNA transcription system and synthesize their own viral RNAs.
    Spectrum Effective against viruses causing influenza A and influenza B, including strains resistant to current antiviral agents.
    Microbiology Applications Viruses have been detected that are resistant to Baloxavir Marboxil owing to an I38 mutation of cap-dependent endonuclease (CEN)(Yoshino et al, 2019).

    While it is being studied for COVID-19 no published evidence supports its use to date.

    Eukaryotic Cell Culture Applications Baloxavir Acid was assayed along with a different class of antivirals, the neuraminidase inhibitors (oseltamivir acid, zanamivir hydrate, laninamivir, peramivir trihydrate) to evaluate its effectiveness in combination. Madin-Darby Canine Kidney (MDCK) cells were used in cell viability assays infected with influenza virus A/PR/8/34 strain. Results indicated that Baloxavir Acid (tested at 1.25 – 80 nmol/L) had a synergistic effect in vitro. There was no evidence of cytotoxicity for Baloxavir Acid alone or in combination (Fukao et al, 2019).
    Molecular Formula C27H23F2N3O7S

    Dias A et al (2009) The cap-snatching endonuclease of influenza virus polymerase residues in the PA subunit. Nature 458:914-918 PMID 19194459

    Dong LH and Cao XR (2018) Studies of the interaction of influenza virus RNA polymerase PAN with endonuclease inhibitors. Interdiscip. Sci. 10(2):430-437 PMID 28631174

    Fukao K et al (2019) Combination treatment with the cap-dependent endonuclease inhibitor baloxavir marboxil and a neuraminidase inhibitor in a mouse model of influenza A virus infection. J Antimicrob Chemother. 74(3):654-662 PMID 30476172

    Hayden FG (2018) Baloxavir Marboxil for uncomplicated influenza in adults and adolescents. N. Eng. J Med. 379(10):913-923 PMID 30184455

    Yoshino R, Yasuo N, Sekijima M (2019) Molecular dynamics simulation reveals the mechanism by which the influenza cap-dependent endonuclease acquires resistance against Baloxavir Marboxil. Sci.Rep. 29(1):17464 PMID 31767949